Sophie Barrett - Concepedia

Author

Sophie Barrett

Also Known As

Barrett, Sophie, Chris Holcombe, Gillian Barmack, S Barrett, S. Barrett, S.V Barrett, S.V. Barrett, Sophie Barrett, Sophie V. Barrett, Yung-Chang Lin

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Institute of Cancer Research Beatson West of Scotland Cancer Centre Royal Marsden NHS Foundation Trust King's College London Myriad Genetics

About

Sophie Barrett is an author at Institute of Cancer Research specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.8K
2	Pathology	6	6	1.6K
3	Cell Biology	2	2	875
4	Health Sciences	1	1	19
5	Obstetrics	1	1	82

Sophie Barrett

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial Andrew Tutt, Holly Tovey, Maggie C.U. Cheang, Nature Medicine Tnt TrialBreast OncologyMedicinePathologyBreast Cancer	2018	862
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Phase I and Pharmacodynamic Trial of the DNA Methyltransferase Inhibitor Decitabine and Carboplatin in Solid Tumors Kim Appleton, Helen Mackay, Ian Judson, Journal of Clinical Oncology	2007	228
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. Andrew D. Seidman, Amy Tiersten, Clifford A. Hudis, Journal of Clinical Oncology	1995	204
Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or <i>BRCA1/2</i> breast cancer (CRUK/07/012) Andrew Tutt, Lucy Kilburn, Cheryl Gilett, Cancer Research Tnt TrialTumor BiologyBreast OncologyCancer EpidemiologyMedicine	2015	164
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) Thomas Bachelot, Eva Ciruelos, Fabio Puglisi, Annals of Oncology Metastatic Breast CancerBreast OncologyMedicinePathologyPreliminary Safety	2019	111
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication David Miles, Eva Ciruelos, Fabio Puglisi, Annals of Oncology	2021	83
Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial Sophie Barrett, James Paul, A. Hay, Annals of Oncology Does BodyOverall SurvivalMedicineGynecologyCancer Registration	2008	82
Anti-sleeping Sickness Drugs and Cancer Chemotherapy Sophie Barrett, Michael P. Barrett Parasitology Today Medicinal ChemistrySleepOncologySleep DisorderAnti-sleeping Sickness Drugs	2000	64
Oncoplastic breast conservation does not lead to a delay in the commencement of adjuvant chemotherapy in breast cancer patients Jeffrey Kahn, Sophie Barrett, C. Braço Forte, European Journal of Surgical Oncology Surgical OncologyOncologyBreast OncologyBreast Cancer PatientsAdjuvant Chemotherapy	2013	60

Page 1